1,033 results match your criteria: "" Centre Henri Becquerel[Affiliation]"

Factors associated with enrolment in clinical trials among women with early-stage breast cancer.

ESMO Open

June 2022

INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France. Electronic address:

Background: Clinical trials allow development of innovative treatments and ameliorate the quality of clinical care in oncology. Data show that only a minority of patients are enrolled in clinical trials. We assessed enrolment in clinical trials and its correlates among women with early breast cancer.

View Article and Find Full Text PDF
Article Synopsis
  • Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is an aggressive, rare form of T-cell lymphoma mainly found in Asia, with a clinical study conducted on 71 European patients showing a median age of 67 years.
  • Most patients had gastrointestinal symptoms requiring emergency surgery, with around 40% diagnosed at stage IV, and tumors were classified into typical and atypical morphologies sharing similar immunophenotypic profiles.
  • The study highlighted significant genetic alterations, including mutations in genes like MYC, STAT5B, and TP53, which are associated with poor survival outcomes and treatment resistance, indicating the high clinical risk of MEITL.
View Article and Find Full Text PDF

Introduction: Stereotactic body radiotherapy (SBRT) is a treatment option for spine metastases. The International Spine Radiosurgery Consortium (ISRC) has published consensus guidelines for target delineation in spine SBRT. A new software called Elements™ Spine SRS by Brainlab that includes the module Elements SmartBrush Spine (v3.

View Article and Find Full Text PDF
Article Synopsis
  • Stage IIB Hodgkin lymphoma (HL) patients with certain risk factors have a poor prognosis and are treated either as limited or advanced stage, with differing clinical trials comparing these treatment approaches.
  • A study involving 148 patients showed that baseline total metabolic tumor volume (TMTV) and responses after two cycles of chemotherapy significantly influenced progression-free survival rates, with a median follow-up of 4.1 years showing PFS rates around 88%.
  • The findings suggest that both upfront ABVD plus radiation therapy and upfront escBEACOPP without radiotherapy yield similar outcomes in these high-risk patients, while TMTV can effectively stratify their risk at baseline.
View Article and Find Full Text PDF

Alexandre Huat, Sébastien Thureau, David Pasquier, Isabelle Gardin, Romain Modzelewski, David Gibon, Juliette Thariat and Vincent Grégoire were not included as authors in the original publication [...

View Article and Find Full Text PDF

Background: The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort.

Methods: A total of 780 patients with AML in first complete remission, with either intermediate- or adverse-risk cytogenetics, whose TP53 mutation status was reported, were included in this study from the European Society for Blood and Marrow Transplantation.

Results: Two-year overall survival (OS) was impaired in patients (n = 179) with evidence of a TP53 mutation at diagnosis (35.

View Article and Find Full Text PDF
Article Synopsis
  • High-dose melphalan (HDM) combined with bortezomib (Bor-HDM) was tested in a phase 3 trial for patients with multiple myeloma to see if it was more effective than HDM alone.* -
  • The trial included 300 patients, and results showed no significant differences in complete response rates or minimum residual disease rates between the two treatment groups.* -
  • Although progression-free survival was slightly better in the Bor-HDM group (34.0 months) compared to HDM (29.6 months), the overall survival rates and serious adverse events were similar, indicating Bor-HDM did not provide a clear advantage.*
View Article and Find Full Text PDF

Skin damage is the most common and most important toxicity during and after radiation therapy (RT). Its assessment and understanding of the factors influencing its occurrence, is a major issue in the management of patients irradiated for an early breast cancer. CANTO is a prospective clinical cohort study of 10 150 patients with stage I-III BC treated from 2012 to 2017 in 26 cancer centres.

View Article and Find Full Text PDF
Article Synopsis
  • CD19 is an ideal therapeutic target due to its widespread expression in certain cancers, effective internalization in cells, minimal off-target effects, and strong specificity for diseases like B-cell non-Hodgkin lymphoma.
  • Existing anti-CD19 therapies show promise for patients with relapsed or refractory forms of this lymphoma, but treatment choices should be personalized based on patient needs and therapy goals.
  • There is currently a lack of comprehensive data on how to best sequence different anti-CD19 therapies, prompting a review of their effectiveness in treating diffuse large B-cell lymphoma.
View Article and Find Full Text PDF

Background: Art therapy (AT) as supportive care may help patients cope with cancer treatments. This non-blinded randomized trial assessed the impact of creative AT on severe fatigue and quality of life (QoL) in localized breast cancer patients undergoing irradiation.

Material And Methods: 320 patients were randomized to an AT group (ATG; 8 weekly sessions starting during irradiation) or to a standard group (SG).

View Article and Find Full Text PDF

Context: Bone marrow biopsy (BMB) is a common procedure in haematology used for the diagnosis and evaluation of response treatment. Because the procedure is difficult for haematologists to perform, patients often experience pain and stress. On Control, a system device, was introduced in the 2000s and uses a drill-powered needle to perform BMB.

View Article and Find Full Text PDF

In this paper, we propose to quantitatively compare loss functions based on parameterized Tsallis-Havrda-Charvat entropy and classical Shannon entropy for the training of a deep network in the case of small datasets which are usually encountered in medical applications. Shannon cross-entropy is widely used as a loss function for most neural networks applied to the segmentation, classification and detection of images. Shannon entropy is a particular case of Tsallis-Havrda-Charvat entropy.

View Article and Find Full Text PDF
Article Synopsis
  • * Distinguishing cHCL from similar conditions like variant hairy cell leukemia (vHCL) and splenic diffuse red pulp lymphoma (SDRPL) can be difficult, particularly since some cHCL patients may not express typical markers or mutations.
  • * A study involving deep sequencing found that 93% of cHCL patients had mutations, with some showing clonal evolution; notably, certain mutations were linked to poorer outcomes, suggesting a need for careful monitoring and
View Article and Find Full Text PDF
Article Synopsis
  • Primary cutaneous large B-cell lymphomas (PCLBCL) are hard to diagnose because they come in different types that need different treatments and have different outcomes.
  • Scientists studied 55 PCLBCL cases and found many were classified as either germinal center (GC) or non-GC types, with some unclassified ones needing more testing.
  • They used a special test called RT-MLPA to accurately sort out the different types of PCLBCL, which could help doctors better figure out how to treat patients based on their specific lymphoma type.
View Article and Find Full Text PDF
Article Synopsis
  • MDS-RS patients experience chronic anemia and often become dependent on red blood cell transfusions, with a low risk of developing acute myeloid leukemia.
  • In a 6-month study involving 100 transfusion-dependent patients across 12 French centers, researchers examined transfusion patterns, hospitalization frequency, care costs, and related health issues.
  • Results showed that 79% of patients had a high transfusion burden, leading to increased hospital visits and significant treatment costs (16,188€ per patient), highlighting the need to evaluate more effective treatment options.
View Article and Find Full Text PDF

In order to improve the outcome observed with azacitidine (AZA) in higher-risk Myelodysplastic syndrome (MDS), its combination with other drugs in MDS must be evaluated. So far, no combination has not been shown to be more effective than AZA alone. AZA-PLUS was a phase II trial that, in a "pick a winner" approach, randomly assigned patients with higher-risk MDS, CMML and low blast count AML to: AZA; AZA plus lenalidomide; AZA plus Valproic Acid or AZA plus Idarubicin.

View Article and Find Full Text PDF

Karyotype complexity has major prognostic value in many malignancies. There is no consensus on the definition of a complex karyotype, and the prognostic impact of karyotype complexity differs from one disease to another. Due to the importance of the complex karyotype in the prognosis and treatment of several hematological diseases, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) has developed an up-to-date, practical document for helping cytogeneticists to assess complex karyotypes in these hematological disorders.

View Article and Find Full Text PDF
Article Synopsis
  • * The study found that patients receiving treatment at first relapse and those treated with specific chemotherapy combinations faced poorer prognoses and higher treatment-related mortality, especially when SCAT was administered beyond the first relapse.
  • * Overall survival rates were significant, with 5-year survival at 80% for first-line treatment and 50% for first-relapse treatment, indicating the importance of timing in ASCT to improve the benefit/risk ratio for different chemotherapy regimens.
View Article and Find Full Text PDF

The clinical actionability of circulating tumor DNA requires sensitive detection methods with a short turnaround time. In the PADA-1 phase 3 trial (NCT03079011), metastatic breast cancer patients treated with an aromatase inhibitor and palbociclib were screened every 2 months for activating mutations in blood (). We report the feasibility of the droplet digital polymerase chain reaction (ddPCR) and cross-validation with next-generation sequencing (NGS).

View Article and Find Full Text PDF

Corrigendum to "De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): characteristics and prognosis" [Eur J Cancer 158 (2021) 181-188].

Eur J Cancer

May 2022

Department of Surgical Oncology, Institut Curie, Paris & Saint-Cloud, France; Inserm U900, Cancer et Génome: Bioinformatique, Biostatistiques et épidémiologie, Institut Curie, Saint-Cloud, France.

View Article and Find Full Text PDF

Nodal peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) with cytotoxic phenotype is overall rare, with most reports coming from Asia. Given its elusive pathobiology, we undertook a clinicopathological and molecular study of 54 Western patients diagnosed with PTCL, NOS expressing cytotoxic molecules, within a lymph node. More commonly males (M/F-2,6/1) with median age of 60 years were affected.

View Article and Find Full Text PDF

Purpose: Trastuzumab-emtansine (T-DM1), as well as lapatinib plus capecitabine were proven effective in two Phase III studies, following first-line trastuzumab plus a taxane. The introduction of dual HER2 blockade by trastuzumab and pertuzumab as first-line has positioned T-DM1 into second-line, and lapatinib plus capecitabine beyond, without formal evaluation of these strategies.

Methods: ESME Data Platform (NCT03275311) included individual data from all patients aged ≥18 years, in whom first-line treatment for metastatic breast cancer (MBC) was initiated between January 1, 2008 and December 31, 2016 in one of the 18 French Comprehensive Cancer Centers.

View Article and Find Full Text PDF